The burden and trend of liver metastases in Shanghai, China: a population-based study
- PMID: 37401477
- DOI: 10.1097/CEJ.0000000000000823
The burden and trend of liver metastases in Shanghai, China: a population-based study
Abstract
Background: Studies on the epidemiology of liver metastases (LM)-related mortality are rare. we aimed to describe the burden and trend of liver metastases in Pudong of Shanghai, which could be beneficial to cancer prevention.
Methods: We performed a retrospective population-based analysis of cancer mortality data with liver metastases in Shanghai Pudong from 2005 to 2021. Long-term trends in crude mortality rates (CMRs), age-standardized mortality rates worldwide, and rate of years of life lost (YLL) were analyzed by the Join-point regression model. In addition, we evaluate the impact of the demographic and nondemographic factors on the mortality of disease by the decomposition method.
Results: Cancer with liver metastases accounted for 26.68% of all metastases. The CMR and age-standardized mortality rates by Segi's world population (ASMRW) of cancer with liver metastases were 15.12/105 person-years and 6.33/105 person-years, respectively. The YLL from cancer with liver metastases was 84 959.87 years, with the age group of 60-69 years having the highest YLL of 26 956.40 years. The top three cancer types in liver metastases are colorectal, gastric, and pancreatic cancer. The long-term trend of ASMRW significantly decreased by 2.31% per year ( P <0.05). The ASMRW and YLL rates of those over 45 decreased year by year. Particularly striking was the 70-79 age group. Although the overall mortality of cancer with liver metastases decreased, there was still a significant upward trend toward an increased mortality rate caused by cancer with liver metastases in aging patients.
Conclusion: Liver metastases were a common site of metastases in patients with cancers originating from the digestive system. The disease burden caused by cancer with liver metastases provides valuable evidence for cancer management.
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
References
-
- Abbott DE, Sohn VY, Hanseman D, Curley SA (2014). Cost-effectiveness of simultaneous resection and RFA versus 2-stage hepatectomy for bilobar colorectal liver metastases. J Surg Oncol 109:516–520.
-
- Alzubi MA, Sohal SS, Sriram M, Turner TH, Zot P, Idowu M, et al. (2019). Quantitative assessment of breast cancer liver metastasis expansion with patient-derived xenografts. Clin Exp Metastasis 36:257–269.
-
- Brawley OW, Paller CJ (2021). The realities of prostate cancer screening, treatment, and race. J Natl Cancer Inst 113:1272–1273.
-
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424.
-
- Budh DP, Sapra A (2022). Breast Cancer Screening. In: StatPearls. StatPearls Publishing Copyright © 2022, StatPearls Publishing LLC.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical